CR20170383A - Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 - Google Patents
Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123Info
- Publication number
- CR20170383A CR20170383A CR20170383A CR20170383A CR20170383A CR 20170383 A CR20170383 A CR 20170383A CR 20170383 A CR20170383 A CR 20170383A CR 20170383 A CR20170383 A CR 20170383A CR 20170383 A CR20170383 A CR 20170383A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- biespecific
- specifically join
- specifically binds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Abstract
La presente invención se refiere a una proteína de unión semejante a anticuerpo que se une específicamente a CD3 y que se une específicamente al menos a un antígeno adicional, por ejemplo CD123. La presente invención también se refiere a una proteína de unión semejante a anticuerpo que se une específicamente a CD123 y que se une específicamente al menos a un antígeno adicional. La invención se refiere además a anticuerpos anti-CD3 y anticuerpos anti-CD123.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15305077 | 2015-01-23 | ||
PCT/EP2016/051386 WO2016116626A1 (en) | 2015-01-23 | 2016-01-22 | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20170383A true CR20170383A (es) | 2017-11-22 |
Family
ID=52434717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20170383A CR20170383A (es) | 2015-01-23 | 2016-01-22 | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
Country Status (37)
Country | Link |
---|---|
US (3) | US20180057597A1 (es) |
EP (3) | EP4039710A3 (es) |
JP (3) | JP6817211B2 (es) |
KR (1) | KR20170101311A (es) |
CN (3) | CN114230668A (es) |
AR (1) | AR103488A1 (es) |
AU (2) | AU2016210068B2 (es) |
BR (1) | BR112017014805A2 (es) |
CA (1) | CA2974453A1 (es) |
CL (2) | CL2017001866A1 (es) |
CO (1) | CO2017008462A2 (es) |
CR (1) | CR20170383A (es) |
DO (1) | DOP2017000160A (es) |
EA (1) | EA201791666A1 (es) |
EC (1) | ECSP17054182A (es) |
ES (1) | ES2824167T3 (es) |
GT (1) | GT201700162A (es) |
HR (1) | HRP20201517T1 (es) |
HU (1) | HUE052011T2 (es) |
IL (2) | IL299975A (es) |
LT (1) | LT3247725T (es) |
MA (1) | MA40801A1 (es) |
MX (3) | MX2017009535A (es) |
MY (1) | MY191964A (es) |
NZ (1) | NZ734803A (es) |
PE (1) | PE20171764A1 (es) |
PH (1) | PH12017501190A1 (es) |
PL (1) | PL3247725T3 (es) |
PT (1) | PT3247725T (es) |
RS (1) | RS60916B1 (es) |
SG (2) | SG11201705925PA (es) |
SI (1) | SI3247725T1 (es) |
TN (3) | TN2018000325A1 (es) |
TW (3) | TWI726862B (es) |
UA (1) | UA126269C2 (es) |
UY (1) | UY36536A (es) |
WO (1) | WO2016116626A1 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
ES2824167T3 (es) | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
PE20181167A1 (es) | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
FI3443006T3 (fi) | 2016-04-13 | 2023-10-23 | Sanofi Sa | Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja |
SG11201808911SA (en) | 2016-04-13 | 2018-11-29 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
TWI784957B (zh) | 2016-06-20 | 2022-12-01 | 英商克馬伯有限公司 | 免疫細胞介素 |
TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
BR112019005333A2 (pt) | 2016-09-21 | 2019-06-11 | Aptevo Research And Development Llc | proteínas de ligação a cd123 e composições e métodos relacionados |
CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
JP7202185B2 (ja) * | 2016-12-22 | 2023-01-11 | 第一三共株式会社 | 抗cd3抗体及び該抗体を含む分子 |
SG10201912368XA (en) * | 2017-02-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
CN110831965B (zh) | 2017-06-21 | 2023-03-07 | 吉利德科学公司 | 靶向hiv gp120和cd3的多特异性抗体 |
US11525004B2 (en) | 2017-07-20 | 2022-12-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Recombinant CD123-binding antibodies |
EP3684806A4 (en) * | 2017-09-21 | 2021-09-22 | Wuxi Biologics (Cayman) Inc. | NEW ANTI-CD3EPSILON ANTIBODIES |
EP4249068A3 (en) | 2017-10-10 | 2023-11-22 | Sanofi | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies |
JP7438106B2 (ja) | 2017-10-14 | 2024-02-26 | シートムエックス セラピューティクス,インコーポレイテッド | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 |
CA3205442A1 (en) * | 2017-10-27 | 2019-05-02 | Pfizer, Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
AU2019206648A1 (en) | 2018-01-12 | 2020-07-16 | Genzyme Corporation | Methods for the quantitation of polypeptides |
US11685781B2 (en) * | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
JOP20200302A1 (ar) * | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | الأجسام المضادة لـ cd3 واستخداماتها |
CN116425874A (zh) * | 2018-06-15 | 2023-07-14 | 康源博创生物科技(北京)有限公司 | 抗cd123抗体及其制备方法和应用 |
WO2019244107A1 (en) * | 2018-06-21 | 2019-12-26 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
WO2020001344A1 (en) * | 2018-06-29 | 2020-01-02 | Beijing Biocytogen Co., Ltd | ANTI-CD3e ANTIBODIES AND USES THEREOF |
EP4268831A2 (en) | 2018-09-12 | 2023-11-01 | Fred Hutchinson Cancer Center | Reducing cd33 expression to selectively protect therapeutic cells |
BR112021006558A2 (pt) | 2018-10-09 | 2021-07-13 | Sanofi | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral |
WO2020123662A2 (en) * | 2018-12-11 | 2020-06-18 | AdMIRx Inc. | Fusion protein constructs for complement associated disease |
EP3902823A1 (en) | 2018-12-24 | 2021-11-03 | Sanofi | Multispecific binding proteins with mutant fab domains |
SG11202111012QA (en) * | 2019-04-09 | 2021-11-29 | Sanofi Sa | Trispecific binding proteins, methods, and uses thereof |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
MX2022002024A (es) * | 2019-08-17 | 2022-03-11 | Igm Biosciences Inc | Moleculas de union anti-cd123 multimericas biespecificas y usos de estas. |
JP7227895B2 (ja) * | 2019-12-23 | 2023-02-22 | 株式会社堀場製作所 | 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット |
EP4090365A1 (en) | 2020-01-15 | 2022-11-23 | Immatics Biotechnologies GmbH | Antigen binding proteins specifically binding prame |
CN111349163A (zh) | 2020-02-05 | 2020-06-30 | 北京智仁美博生物科技有限公司 | 针对cd123的单克隆抗体 |
US20230348571A1 (en) * | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
TW202210510A (zh) * | 2020-05-27 | 2022-03-16 | 美商健生生物科技公司 | 包含cd3抗原結合域之蛋白質及其用途 |
IL300314A (en) | 2020-10-08 | 2023-04-01 | Affimed Gmbh | Coupling materials with triple specificity |
AU2021414400A1 (en) * | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
TW202241967A (zh) * | 2021-01-11 | 2022-11-01 | 美商索特里亞生物治療藥物公司 | 基於茚地那韋的化學二聚化t細胞銜接器組成物 |
WO2022165171A1 (en) | 2021-01-28 | 2022-08-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
CN117120471A (zh) * | 2021-03-23 | 2023-11-24 | 广州凌腾生物医药有限公司 | 结合cd3的多特异性抗原结合蛋白及其用途 |
BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
US20230077531A1 (en) | 2021-05-27 | 2023-03-16 | Sanofi | Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY |
AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
WO2023061419A1 (en) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins |
WO2023072217A1 (en) * | 2021-10-28 | 2023-05-04 | Guangzhou Lintonpharm Co., Ltd. | Fusion proteins targeting cd3 and cd47 |
CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023183600A1 (en) * | 2022-03-25 | 2023-09-28 | Washington University | Systems and methods for monitoring efficacy of cytotoxic treatment |
TW202346337A (zh) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3及cd3結合劑以及其使用方法 |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2023250434A2 (en) * | 2022-06-22 | 2023-12-28 | The Regents Of The University Of Michigan | Compositions and methods for targeted ides treatment of igg-related disorders |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024061352A1 (zh) * | 2022-09-23 | 2024-03-28 | 广州凌腾生物医药有限公司 | 分离的抗原结合蛋白及其应用 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204A (en) | 1847-07-24 | james cantelo | ||
US244A (en) | 1837-06-30 | Edward flint | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69032484D1 (de) | 1989-10-27 | 1998-08-20 | Arch Dev Corp | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation |
US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
DE69131017T2 (de) | 1990-12-20 | 1999-07-15 | Ixsys Inc | Optimierung von bindenden proteinen |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2156725A1 (en) | 1993-02-22 | 1994-09-01 | Warren S. Pear | Production of high titer helper-free retroviruses by transient transfection |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
JP3946256B2 (ja) | 1995-09-11 | 2007-07-18 | 協和醗酵工業株式会社 | ヒトインターロイキン5受容体α鎖に対する抗体 |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
CA2287084A1 (en) | 1997-04-10 | 1998-10-15 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method and reagents |
DE19721700C1 (de) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutierter OKT3-Antikörper |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
AU5003001A (en) | 2000-03-06 | 2001-09-17 | Univ Kentucky Res Found | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
WO2004094613A2 (en) | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
CN1984931B (zh) * | 2004-06-03 | 2012-11-28 | 诺维莫尼公司 | 抗-cd3抗体及其使用方法 |
CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发(慕尼黑)股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
LT2520590T (lt) * | 2007-04-03 | 2018-09-10 | Amgen Research (Munich) Gmbh | Susijusioms rūšims specifinis rišantis domenas |
CA2698203C (en) | 2007-08-29 | 2018-09-11 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their use |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
DK2356153T3 (en) | 2008-10-01 | 2016-07-04 | Amgen Res (Munich) Gmbh | Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES |
WO2010126066A1 (ja) | 2009-04-27 | 2010-11-04 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗IL-3Rα抗体 |
NZ601760A (en) | 2010-02-17 | 2013-10-25 | Csl Ltd | Compositions and methods for targeting type 1 interferon producing cells |
WO2011109588A1 (en) * | 2010-03-03 | 2011-09-09 | Health Research Inc. | Novel cd3 epsilon immunogens and antibodies |
EP2582390B1 (en) * | 2010-06-15 | 2014-11-19 | CSL Limited | Immunotherapeutic method involving cd123 (il-3r ) antibodies and immunostimulating complex |
NZ604510A (en) * | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
SG195072A1 (en) | 2011-05-21 | 2013-12-30 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
CN102796198A (zh) | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | 抗CD3抗体Fv片段与白介素3的融合蛋白、制备方法及其用途 |
CN102796199A (zh) * | 2011-05-26 | 2012-11-28 | 中国医学科学院血液病医院 | 抗CD3抗体Fv片段与白介素3融合蛋白突变体、制备方法及其用途 |
EP2809682B1 (en) | 2012-02-03 | 2020-04-08 | F.Hoffmann-La Roche Ag | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
EP2839019A4 (en) | 2012-04-20 | 2016-03-30 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
EP4053162A1 (en) * | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
US9915665B2 (en) | 2012-12-28 | 2018-03-13 | Abbvie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
JP2016093104A (ja) * | 2013-02-19 | 2016-05-26 | 国立大学法人京都大学 | 抗ヒトCD3ε抗体又はそのフラグメント、及びそれを有効成分とする免疫抑制剤 |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
IL275376B2 (en) * | 2013-03-11 | 2024-01-01 | Genzyme Corp | Polypeptides with hyperglycosidic bonds |
US20160046718A1 (en) | 2013-03-14 | 2016-02-18 | Csl Limited | Agents that neutralize il-3 signalling and uses thereof |
US20160031996A1 (en) * | 2013-03-14 | 2016-02-04 | Csl Limited | Anti il-3r alpha agents and uses thereof |
AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
EP3424952A1 (en) | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
SG11201509361TA (en) * | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EA037647B1 (ru) | 2014-09-05 | 2021-04-27 | Янссен Фармацевтика Нв | Агенты, связывающиеся с cd123, и виды их применения |
ES2824167T3 (es) | 2015-01-23 | 2021-05-11 | Sanofi Sa | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 |
KR20180018525A (ko) | 2015-05-08 | 2018-02-21 | 젠코어 인코포레이티드 | Cd3 및 종양 항원과 결합하는 이종이량체 항체 |
TWI790206B (zh) | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白 |
-
2016
- 2016-01-22 ES ES16701353T patent/ES2824167T3/es active Active
- 2016-01-22 KR KR1020177023344A patent/KR20170101311A/ko active IP Right Grant
- 2016-01-22 PE PE2017001243A patent/PE20171764A1/es unknown
- 2016-01-22 HU HUE16701353A patent/HUE052011T2/hu unknown
- 2016-01-22 CR CR20170383A patent/CR20170383A/es unknown
- 2016-01-22 EA EA201791666A patent/EA201791666A1/ru unknown
- 2016-01-22 AR ARP160100178A patent/AR103488A1/es unknown
- 2016-01-22 TN TNP/2018/000325A patent/TN2018000325A1/en unknown
- 2016-01-22 PL PL16701353T patent/PL3247725T3/pl unknown
- 2016-01-22 SI SI201630932T patent/SI3247725T1/sl unknown
- 2016-01-22 TN TNP/2018/000324A patent/TN2018000324A1/en unknown
- 2016-01-22 IL IL299975A patent/IL299975A/en unknown
- 2016-01-22 EP EP22152787.2A patent/EP4039710A3/en active Pending
- 2016-01-22 EP EP16701353.1A patent/EP3247725B1/en active Active
- 2016-01-22 EP EP20170198.4A patent/EP3812398A3/en not_active Withdrawn
- 2016-01-22 MY MYPI2017702398A patent/MY191964A/en unknown
- 2016-01-22 JP JP2017538599A patent/JP6817211B2/ja active Active
- 2016-01-22 TN TN2017000275A patent/TN2017000275A1/en unknown
- 2016-01-22 SG SG11201705925PA patent/SG11201705925PA/en unknown
- 2016-01-22 NZ NZ734803A patent/NZ734803A/en unknown
- 2016-01-22 SG SG10201906762YA patent/SG10201906762YA/en unknown
- 2016-01-22 TW TW105102149A patent/TWI726862B/zh active
- 2016-01-22 MA MA40801A patent/MA40801A1/fr unknown
- 2016-01-22 LT LTEP16701353.1T patent/LT3247725T/lt unknown
- 2016-01-22 UA UAA201708583A patent/UA126269C2/uk unknown
- 2016-01-22 BR BR112017014805-6A patent/BR112017014805A2/pt active Search and Examination
- 2016-01-22 MX MX2017009535A patent/MX2017009535A/es unknown
- 2016-01-22 PT PT167013531T patent/PT3247725T/pt unknown
- 2016-01-22 TW TW110113349A patent/TW202130662A/zh unknown
- 2016-01-22 CA CA2974453A patent/CA2974453A1/en active Pending
- 2016-01-22 RS RS20201167A patent/RS60916B1/sr unknown
- 2016-01-22 CN CN202111365671.4A patent/CN114230668A/zh active Pending
- 2016-01-22 WO PCT/EP2016/051386 patent/WO2016116626A1/en active Application Filing
- 2016-01-22 CN CN201680017477.8A patent/CN107428835B/zh active Active
- 2016-01-22 TW TW112134826A patent/TW202402802A/zh unknown
- 2016-01-22 CN CN202111365516.2A patent/CN114230667A/zh active Pending
- 2016-01-22 AU AU2016210068A patent/AU2016210068B2/en active Active
- 2016-01-25 UY UY0001036536A patent/UY36536A/es not_active Application Discontinuation
-
2017
- 2017-06-23 PH PH12017501190A patent/PH12017501190A1/en unknown
- 2017-07-04 DO DO2017000160A patent/DOP2017000160A/es unknown
- 2017-07-19 CL CL2017001866A patent/CL2017001866A1/es unknown
- 2017-07-19 IL IL253569A patent/IL253569B2/en unknown
- 2017-07-20 GT GT201700162A patent/GT201700162A/es unknown
- 2017-07-20 US US15/654,857 patent/US20180057597A1/en not_active Abandoned
- 2017-07-21 MX MX2021011696A patent/MX2021011696A/es unknown
- 2017-07-21 MX MX2021011697A patent/MX2021011697A/es unknown
- 2017-08-21 EC ECIEPI201754182A patent/ECSP17054182A/es unknown
- 2017-08-22 CO CONC2017/0008462A patent/CO2017008462A2/es unknown
-
2018
- 2018-04-02 US US15/943,685 patent/US10906978B2/en active Active
- 2018-08-31 CL CL2018002490A patent/CL2018002490A1/es unknown
-
2020
- 2020-09-22 HR HRP20201517TT patent/HRP20201517T1/hr unknown
- 2020-12-23 JP JP2020213051A patent/JP7269215B2/ja active Active
-
2021
- 2021-01-12 US US17/147,255 patent/US20210292423A1/en active Pending
-
2022
- 2022-01-25 AU AU2022200467A patent/AU2022200467A1/en active Pending
-
2023
- 2023-04-20 JP JP2023068919A patent/JP2023093625A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
ECSP17081420A (es) | Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales | |
CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
IL264334A (en) | Anti-gprc5d antibodies, bispecific antigen-binding molecules that bind gprc5d and cd3 and uses thereof | |
MX2020001879A (es) | Proteínas de fijación al antígeno que se dirigen a antígenos compartidos. | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CR20180225A (es) | Anticuerpo anti-tigit y métodos de uso | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
CR20170026A (es) | Anticuerpos anti-tau humanizados | |
CR20150575A (es) | Anticuerpos humanos pac1 | |
AR105267A1 (es) | Anticuerpos de unión a tau | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
PE20230381A1 (es) | Proteina de union a rgma | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
BR112015021964A2 (pt) | Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
MX2019003908A (es) | Metodo por multiproteasa. | |
ECSP21028958A (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
MX2021007369A (es) | Combinacion farmaceutica de anticuerpos anti ceacam6 y tim3. | |
EA201691414A1 (ru) | Антитела к матриксной металлопротеиназе 9 и способы их применения | |
EA202091181A3 (ru) | Антитела и способы их применения |